Gilteritinib induces differentiation in relapsed and refractory FLT3-mutated acute myeloid leukemia

Blood Adv. 2019 May 28;3(10):1581-1585. doi: 10.1182/bloodadvances.2018029496.

Abstract

  1. Gilteritinib induces 2 distinct marrow responses in FLT3-mutated AML: responses with and without differentiation.

  2. Ongoing clonal hematopoiesis is ubiquitous during gilteritinib therapy and may promote genetic evolution and drug resistance.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aniline Compounds / pharmacology
  • Aniline Compounds / therapeutic use*
  • Cell Differentiation
  • Humans
  • Leukemia, Myeloid, Acute / drug therapy*
  • Leukemia, Myeloid, Acute / genetics*
  • Pyrazines / pharmacology
  • Pyrazines / therapeutic use*
  • Recurrence
  • fms-Like Tyrosine Kinase 3 / metabolism*

Substances

  • Aniline Compounds
  • Pyrazines
  • gilteritinib
  • FLT3 protein, human
  • fms-Like Tyrosine Kinase 3